For US Health Care Professionals Only
GETTING PATIENTS STARTED

For your convenience, there are 3 ways to get patients started on GILENYA:

Getting Patients Started

Recommended Dosage

  • In adults and pediatric patients 10 years of age and older weighing more than 40 kg, the recommended dosage of GILENYA is 0.5 mg orally once-daily
  • In pediatric patients 10 years of age and older weighing less than or equal to 40 kg, the recommended dosage of GILENYA is 0.25 mg orally once daily
  • Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit
Baseline Assessments
Baseline Assessments Confirm Patients Appropriate to Start GILENYA
Before starting treatment with GILENYA, baseline assessments should be established by the patient’s respective health care provider(s). Confirm these exams and review the results before initiation.
Cardiac Evaluation: Cardiac evaluation in patients with certain pre-existing conditions
  • Prior to starting treatment, determine whether patients are taking drugs that could slow heart rate or atrioventricular conduction
Recent (within 6 months) complete blood count and liver function tests
Prior Medications: If patients are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with GILENYA
History of chickenpox or varicella zoster virus (VZV) serology/vaccination
Examination of the fundus including the macula
Discuss risk with pregnancy
First Dose
ECG prior to first dosing and at the end of observation period
Observe for at least 6 hours, with hourly pulse and blood pressure measurements.  More >
Additional monitoring after 6 hours
  • Continue monitoring until resolution if:
    • The heart rate 6 hours postdose is less than 45 bpm in adults, less than 55 bpm in pediatric patients 12 years of age and older, or less than 60 bpm in pediatric patients 10 or 11 years of age
    • The heart rate 6 hours postdose is at the lowest value postdose suggesting that the maximum pharmacodynamics effect on the heart may not have occurred
    • The ECG 6 hours postdose shows new onset second degree or higher AV block
Overnight monitoring
  • Continuous overnight ECG monitoring should be instituted in patients:
    • That require pharmacologic intervention for symptomatic bradycardia. Repeat first-dose monitoring after the second dose of GILENYA
    • With some preexisting heart and cerebrovascular conditions
    • With a prolonged QTc interval before dosing or during 6-hour observation, or at additional risk for QT prolongation, or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes
    • Receiving concurrent therapy with drugs that slow heart rate or AV conduction
Additional monitoring after 6 hours
  • Continue monitoring until resolution if:
    • The heart rate 6 hours postdose is less than 45 bpm in adults, less than 55 bpm in pediatric patients 12 years of age and older, or less than 60 bpm in pediatric patients 10 or 11 years of age
    • The heart rate 6 hours postdose is at the lowest value postdose suggesting that the maximum pharmacodynamics effect on the heart may not have occurred
    • The ECG 6 hours postdose shows new onset second degree or higher AV block
Overnight monitoring
  • Continuous overnight ECG monitoring should be instituted in patients:
    • That require pharmacologic intervention for symptomatic bradycardia. Repeat first-dose monitoring after the second dose of GILENYA
    • With some preexisting heart and cerebrovascular conditions
    • With a prolonged QTc interval before dosing or during 6-hour observation, or at additional risk for QT prolongation, or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes
    • Receiving concurrent therapy with drugs that slow heart rate or AV conduction
Repeat first-dose monitoring if GILENYA treatment is reinitiated
  • In pediatric patients changing dose from 0.25 mg to 0.5 mg
  • In patients after discontinuation
    • for ≥1 day during the first 2 weeks of treatment
    • for >7 days during weeks 3 or 4 of treatment
    • for >14 days after the first month of treatment
During Treatment
*Heart rate less than 45 beats per minute in adults, less than 55 bpm in pediatric patients 12 years of age and older, or less than 60 bpm in pediatric patients 10 or 11 years of age.
Within weeks 1 and 2 of treatment for interruptions ≥1 day, within weeks 3 and 4 for interruptions >7 days, and after 1 month of treatment for interruptions >14 days.
 
References: 1. Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2018. 2. Kappos L, Radue E-W, O’Connor P, et al; for FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. 3. Cohen JA, Barkhof F, Comi G, et al; for TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415. 4. Data on file. Summary of Clinical Efficacy in Multiple Sclerosis. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2009. 5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology. 1983;33(11):1444-1452. 6. Data on file. CSR 2302. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 7. Data on file. CSR 2301. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 8. Ge Y. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol. 2006;27(6):1165-1176. 9. Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: The McGraw-Hill Companies, Inc; 2008:2611-2621. 10. Data on file. Briefing document. Novartis Pharmaceuticals Corp; East Hanover, NJ. May 2010. 11. Data on file. GILENYA exposure: May 2018 cutoff. Novartis Pharmaceuticals Corp; July 2018. 12. Data on file. Hub SRF and Sales Table. Novartis Pharmaceuticals Corp. Q4 2017. 13. Data on file. CSR 2309. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 14. Chun J, Hartung H-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91-101. 15. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181-195. 16. Data on file. GILENYA exposure: February 2018 cutoff. Novartis Pharmaceuticals Corp; May 2018. 17. DiMarco JP, O’Connor P, Cohen JA, et al. First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Relat Disord. 2014;3(5):629-638. 18. Degaute JP, van de Borne P, Linkowski P, et al. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991;18(2):199-210. 19. Zdanowicz MM, Lynch LM. Teaching the pharmacology of antiarrhythmic drugs. Am J Pharm Educ. 2011;75(7):139. 20. Ganusov VV, De Boer RJ. Do most lymphocytes in humans reside in the gut? Trends Immunol. 2007;28(12):514-518. 21. Zhang ZQ, Notemans DQ, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95(3):1154-1159. 22. Haynes BF, Soderberg KA, Fauci AS. Introduction to the immune system. In: Fauci AS, ed. Harrison’s Rheumatology. 2nd ed. New York, NY: The McGraw-Hill Companies; 2010:2-43. 23. Aubagio [prescribing information]. Cambridge, MA: Genzyme Corp; October 2014a.